CHIRUMBOLO, GABRIELLA
 Distribuzione geografica
Continente #
NA - Nord America 99
EU - Europa 43
AS - Asia 14
AF - Africa 1
SA - Sud America 1
Totale 158
Nazione #
US - Stati Uniti d'America 91
FR - Francia 14
IT - Italia 8
DE - Germania 7
IE - Irlanda 6
IR - Iran 5
MX - Messico 5
TH - Thailandia 4
CN - Cina 3
BE - Belgio 2
BG - Bulgaria 2
CA - Canada 2
GB - Regno Unito 2
AE - Emirati Arabi Uniti 1
BZ - Belize 1
CH - Svizzera 1
CL - Cile 1
HK - Hong Kong 1
NL - Olanda 1
UG - Uganda 1
Totale 158
Città #
Ashburn 12
Columbus 8
Seattle 7
Dublin 6
Santa Cruz 6
Cuauhtemoc 5
Fairfield 5
Qom 5
Bangkok 4
Bologna 4
New York 4
Waltham 4
Woodbridge 4
El Cerrito 3
Bremen 2
Buffalo 2
Chicago 2
Geel 2
Genoa 2
Houston 2
Ottawa 2
Paris 2
San Diego 2
Shanghai 2
Sofia 2
Southend 2
Washington 2
Amsterdam 1
Ann Arbor 1
Atlanta 1
Boardman 1
Bollate 1
Brockport 1
Central 1
Chandler 1
Crugers 1
Essen 1
Flawil 1
Forlì 1
Henderson 1
Los Angeles 1
Milpitas 1
Mountain View 1
Portland 1
Wilmington 1
Winston-Salem 1
Totale 122
Nome #
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia, file e1dcb334-10fb-7715-e053-1705fe0a6cc9 71
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, file e1dcb339-2ea1-7715-e053-1705fe0a6cc9 54
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters, file 9ef7d348-9e1e-402a-a275-71ad8d77e11f 28
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant, file e1dcb339-3ad2-7715-e053-1705fe0a6cc9 10
Totale 163
Categoria #
all - tutte 591
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 591


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 0 0 0 0 2 1 2
2020/202115 1 2 1 0 1 2 1 2 1 0 3 1
2021/202235 0 2 0 3 1 1 1 3 2 3 14 5
2022/202353 0 1 5 7 3 9 2 3 8 3 10 2
2023/202455 0 0 5 10 0 14 5 4 5 3 9 0
Totale 163